Turning Point Therapeutics is a biotechnology business based in the US. Turning Point Therapeutics shares (TPTX) are listed on the NASDAQ and all prices are listed in US Dollars. Turning Point Therapeutics employs 267 staff and has a trailing 12-month revenue of around $1 million.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $76.01 |
|---|---|
| 52-week range | $0.00 - $0.00 |
| 50-day moving average | $75.36 |
| 200-day moving average | $48.05 |
| Wall St. target price | $71.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-5.57 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $76.01 from 2022-09-07
| 1 week (2023-09-12) | N/A |
|---|---|
| 1 month (2023-08-19) | N/A |
| 3 months (2023-06-19) | N/A |
| 6 months (2023-03-19) | N/A |
| 1 year (2022-09-19) | N/A |
|---|---|
| 2 years (2021-09-23) | -2.55% |
| 3 years (2020-09-23) | 83.57 |
| 5 years (2018-09-19) | N/A |
| Revenue TTM | $1 million |
|---|---|
| Gross profit TTM | $30.8 million |
| Return on assets TTM | -22.13% |
| Return on equity TTM | -36.8% |
| Profit margin | 0% |
| Book value | $15.90 |
| Market Capitalization | $3.8 billion |
TTM: trailing 12 months
We're not expecting Turning Point Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Turning Point Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Turning Point Therapeutics's is -0.1941. This would suggest that Turning Point Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Turning Point Therapeutics has bucked the trend.
Turning Point Therapeutics, Inc. , a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.